AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Phase II study results of vaccine combination released.
2003 MAY 14 - (NewsRx.com & NewsRx.net) -- Xenova Group plc (NASDAQ: XNVA; London Stock Exchange: XEN) has announced the results of an open label, physician-sponsored Phase II "prime-boost" study, targeting the treatment of human papillomavirus (HPV) associated ano-genital intraepithelial neoplasia (AGIN).
The announcement, made at the British Society for Colposcopy & Cervical Pathology (BSCCP) meeting in Manchester on April 12, 2003, relates to a study carried out on 29 patients at three centers in the U.K. Early results indicate that a prime boost strategy, using a combination of Xenova's TA-CIN and TA-HPV candidate therapeutic vaccines, is both safe and well tolerated and has demonstrated clear clinical responses, even in women with longstanding disease.
Human papillomavirus (HPV) is a large family of small DNA viruses associated with a number of conditions ranging from skin warts and genital warts to cervical cancer. Infection with high risk types of HPV (such as HPV16 and HPV18) is strongly associated with ano-genital cancer and its precursor AGIN. These diseases are difficult to treat and have a high recurrence rate.
TA-HPV is an immunotherapeutic vaccine which is being developed for use alongside surgery in the treatment of cervical cancer and for the treatment of high-grade AGIN. TA-CIN is a recombinant fusion protein, designed as a treatment for women with cervical dysplasia. Preclinical studies, conducted by Xenova in conjunction with scientists at Leiden University Medical Centre, The Netherlands, demonstrated that use of TA-CIN together with TA-HPV, resulted in an immune response that was significantly greater than that observed with either product alone. The present trials were designed to evaluate results in women using TA-CIN and TA-HPV in a "prime-boost" combination.
In the reported study, 29 women with stable, non-cervical disease were recruited in three centers: St. Mary's Hospital, Manchester; Llandough Hospital, Cardiff; and Addenbrooke's Hospital, Cambridge. Three doses of TA-CIN were given intramuscularly, at four-weekly intervals, followed four weeks later by a single dose of TA-HPV by dermal scarification. Women have been followed up for 12 weeks following completion of the vaccination schedule. Safety, clinical, and immunological responses, and ...
- Xenova Group plc Successful Results of Phase IIa Trial For Therapeutic Vaccine...
- Press release article from: PR Newswire March 27, 2002 700+ words
...initiated Phase IIa trial of Xenova's TA-HPV therapeutic vaccine at the meeting...genital cancers, such as vulval cancer. TA-HPV is a vaccine containing certain disease...into a carrier vaccinia virus vector. TA-HPV is currently undergoing an open-label...
- Xenova Group plc: Successful Results of Phase IIa and Phase I HPV-Related...
- Press release article from: PR Newswire October 26, 2001 700+ words
...Successful Results of Phase IIa trial of TA-HPV Results from a physician-initiated Phase IIa trial of Xenova's TA-HPV vaccine in women with high grade vulval...demonstrated that a combination of TA-HPV and TA-CIN results in an immune response...
- Xenova Group plc; Xenova Demonstrates Clear Clinical Responses in a...
- Press release article from: PR Newswire April 14, 2003 700+ words
...combination of Xenova's TA-CIN and TA-HPV candidate therapeutic vaccines, is...treat and have a high recurrence rate. TA-HPV is an immunotherapeutic vaccine which...that use of TA-CIN together with TA-HPV, resulted in an immune response that...
- HPV 16 L2E6E7 booster vaccine elicits immune response.
- Magazine article from: Women's Health Weekly October 7, 2004 700+ words
...patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16...boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16...grade VIN, previously primed with TA-HPV, received three booster immunizations...
- Vaccine Targeting HPV Oncogenes Appears Feasible.(human...
- Newspaper article from: Virus Weekly April 3, 2001 700+ words
...Wales They observed the ability of TA-HPV, a new vaccine comprising vaccinia...particularly with types 16 and 18 * The TA-HPV vaccine, a live vaccinia virus constructed...products * Some patients vaccinated with TA-HPV or HPV tumor lysate-pulsed dendritic...
- Vaccine Targeting HPV Oncogenes Appears Feasible.(Brief Article)
- Newspaper article from: Vaccine Weekly April 4, 2001 700+ words
...Wales They observed the ability of TA-HPV, a new vaccine comprising vaccinia...particularly with types 16 and 18 * The TA-HPV vaccine, a live vaccinia virus constructed...products * Some patients vaccinated with TA-HPV or HPV tumor lysate-pulsed dendritic...
- HPV genotyping prior to vaccination holds promise.(human papillomavirus...
- Magazine article from: Medical Laboratory Observer Kim, Jong-Kee March 1, 2009 700+ words
...American Social Health Association reports that HPV is one of the most common STDs in the United States. According to HPV Vaccine Statement published by the Centers...year. The good news is that most genital HPV infections are easily treated and clear...
- HPV infection screening is important for HIV MSM.
- Newspaper article from: Same-Day Surgery October 1, 2009 700+ words
HPV infection screening is important for HIV MSM HIV & HPV connection studied Infectious diseases researchers have...interesting trends involving patients with human papillomavirus (HPV) infection and cancer, as well as HIV seroconversion...
